These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 37347041)

  • 1. Investigation of FGF21 mRNA levels and relative mitochondrial DNA copy number levels and their relation in nonalcoholic fatty liver disease: a case-control study.
    Houshmand M; Zeinali V; Hosseini A; Seifi A; Danaei B; Kamfar S
    Front Mol Biosci; 2023; 10():1203019. PubMed ID: 37347041
    [No Abstract]   [Full Text] [Related]  

  • 2. Liver Mitochondrial DNA Copy Number and Deletion Levels May Contribute to Nonalcoholic Fatty Liver Disease Susceptibility.
    Kamfar S; Alavian SM; Houshmand M; Yadegarazari R; Seifi Zarei B; Khalaj A; Shabab N; Saidijam M
    Hepat Mon; 2016 Dec; 16(12):e40774. PubMed ID: 28123441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibroblast growth factor-21 and omentin-1 hepatic mRNA expression and serum levels in morbidly obese women with non-alcoholic fatty liver disease.
    Waluga M; Kukla M; Zorniak M; Kajor M; Liszka L; Dyaczynski M; Kowalski G; Zadlo D; Waluga E; Olczyk P; Buldak RJ; Berdowska A; Hartleb M
    J Physiol Pharmacol; 2017 Jun; 68(3):363-374. PubMed ID: 28820393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease.
    Dushay J; Chui PC; Gopalakrishnan GS; Varela-Rey M; Crawley M; Fisher FM; Badman MK; Martinez-Chantar ML; Maratos-Flier E
    Gastroenterology; 2010 Aug; 139(2):456-63. PubMed ID: 20451522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between Serum Atypical Fibroblast Growth Factors 21 and 19 and Pediatric Nonalcoholic Fatty Liver Disease.
    Alisi A; Ceccarelli S; Panera N; Prono F; Petrini S; De Stefanis C; Pezzullo M; Tozzi A; Villani A; Bedogni G; Nobili V
    PLoS One; 2013; 8(6):e67160. PubMed ID: 23840612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride.
    Li H; Fang Q; Gao F; Fan J; Zhou J; Wang X; Zhang H; Pan X; Bao Y; Xiang K; Xu A; Jia W
    J Hepatol; 2010 Nov; 53(5):934-40. PubMed ID: 20675007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peripheral blood mononuclear cell mitochondrial copy number and adenosine triphosphate inhibition test in NAFLD.
    Lee AH; Oh JH; Kim HS; Shin JH; Yoon EL; Jun DW
    Front Endocrinol (Lausanne); 2022; 13():967848. PubMed ID: 36353244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatic chemerin mRNA expression is reduced in human nonalcoholic steatohepatitis.
    Pohl R; Haberl EM; Rein-Fischboeck L; Zimny S; Neumann M; Aslanidis C; Schacherer D; Krautbauer S; Eisinger K; Weiss TS; Buechler C
    Eur J Clin Invest; 2017 Jan; 47(1):7-18. PubMed ID: 27797398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma Fibroblast Growth Factor 21 Is Associated With Severity of Nonalcoholic Steatohepatitis in Patients With Obesity and Type 2 Diabetes.
    Barb D; Bril F; Kalavalapalli S; Cusi K
    J Clin Endocrinol Metab; 2019 Aug; 104(8):3327-3336. PubMed ID: 30848827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic STAMP2 mediates recombinant FGF21-induced improvement of hepatic iron overload in nonalcoholic fatty liver disease.
    Kim HY; Kwon WY; Park JB; Lee MH; Oh YJ; Suh S; Baek YH; Jeong JS; Yoo YH
    FASEB J; 2020 Sep; 34(9):12354-12366. PubMed ID: 32721044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.
    Suppli MP; Rigbolt KTG; Veidal SS; Heebøll S; Eriksen PL; Demant M; Bagger JI; Nielsen JC; Oró D; Thrane SW; Lund A; Strandberg C; Kønig MJ; Vilsbøll T; Vrang N; Thomsen KL; Grønbæk H; Jelsing J; Hansen HH; Knop FK
    Am J Physiol Gastrointest Liver Physiol; 2019 Apr; 316(4):G462-G472. PubMed ID: 30653341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liraglutide Decreases Liver Fat Content and Serum Fibroblast Growth Factor 21 Levels in Newly Diagnosed Overweight Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease.
    Li X; Wu X; Jia Y; Fu J; Zhang L; Jiang T; Liu J; Wang G
    J Diabetes Res; 2021; 2021():3715026. PubMed ID: 34660809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Fibroblast Growth Factor 21-Pregnane X Receptor Pathway Downregulates Hepatic CYP3A4 in Nonalcoholic Fatty Liver Disease.
    Woolsey SJ; Beaton MD; Mansell SE; Leon-Ponte M; Yu J; Pin CL; Adams PC; Kim RB; Tirona RG
    Mol Pharmacol; 2016 Oct; 90(4):437-46. PubMed ID: 27482056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatocyte-Secreted Autotaxin Exacerbates Nonalcoholic Fatty Liver Disease Through Autocrine Inhibition of the PPARα/FGF21 Axis.
    Qiu H; Song E; Hu Y; Li T; Ku KC; Wang C; Cheung BMY; Cheong LY; Wang Q; Wu X; Hoo RLC; Wang Y; Xu A
    Cell Mol Gastroenterol Hepatol; 2022; 14(5):1003-1023. PubMed ID: 35931383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sulforaphane ameliorates non-alcoholic fatty liver disease in mice by promoting FGF21/FGFR1 signaling pathway.
    Wu YK; Ren ZN; Zhu SL; Wu YZ; Wang G; Zhang H; Chen W; He Z; Ye XL; Zhai QX
    Acta Pharmacol Sin; 2022 Jun; 43(6):1473-1483. PubMed ID: 34654875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging roles for stress kinase p38 and stress hormone fibroblast growth factor 21 in NAFLD development.
    Liu J; Dalamaga M
    Metabol Open; 2021 Dec; 12():100153. PubMed ID: 34917917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis.
    Puengel T; Lefere S; Hundertmark J; Kohlhepp M; Penners C; Van de Velde F; Lapauw B; Hoorens A; Devisscher L; Geerts A; Boehm S; Zhao Q; Krupinski J; Charles ED; Zinker B; Tacke F
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibroblast growth factor 21 in non-alcoholic fatty liver disease.
    Tucker B; Li H; Long X; Rye KA; Ong KL
    Metabolism; 2019 Dec; 101():153994. PubMed ID: 31672443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Albumin-fused long-acting FGF21 analogue for the treatment of non-alcoholic fatty liver disease.
    Chikamatsu M; Watanabe H; Shintani Y; Murata R; Miyahisa M; Nishinoiri A; Imafuku T; Takano M; Arimura N; Yamada K; Kamimura M; Mukai B; Satoh T; Maeda H; Maruyama T
    J Control Release; 2023 Mar; 355():42-53. PubMed ID: 36690035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant FGF21 Attenuates Polychlorinated Biphenyl-Induced NAFLD/NASH by Modulating Hepatic Lipocalin-2 Expression.
    Kim HY; Yoo YH
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.